

# International panel classifies immunotherapy side effects for the first time

## April 4 2023



**Natural History of irAEs** 



Patterns of irAEs



Response to irAE Treatment

#### Recurrent irAEs:

- · Occur in the same organ
- Occur at least twice after IO discontinuation

#### Delayed/late-onset irAEs:

Occur > 3 months after ICI discontinuation

#### **Chronic irAEs:**

Persist beyond 3 months of ICI discontinuation

#### Two subtypes:

- Chronic + active: Ongoing inflammation, requires ongoing immunosuppression
- Chronic + inactive: Absence of ongoing inflammation, not requiring ongoing immunosuppression

#### Multisystem irAEs:

- Occur concomitantly with another irAE or during treatment for the first irAE
- irAEs occurring in the same or different organ system
- If occurring in the same system, affect different tissues

### Steroid-unresponsive irAEs:

- No clinical improvement after a standard timeframe of guideline-based irAE-directed steroid therapy
- Steroid-refractory irAEs derived no clinical benefit from steroids

#### Steroid-resistant irAEs:

 Derived some clinical benefit without resolution of the event

## Steroid-dependent irAEs:

- Some improvement with guideline-based irAE-directed steroid therapy, however a taper is not possible.
- irAEs requiring ongoing steroids for ≥12 weeks are "chronically steroid-dependent"

Consensus definitions for irAE terminology. ICI, immune checkpoint inhibitor; IO, immuno-oncology; irAE, immune-related adverse event. Credit: *Journal for ImmunoTherapy of Cancer* (2023). DOI: 10.1136/jitc-2022-006398



An international panel of oncology and immunotherapy experts led by RCSI's Professor Jarushka Naidoo, has developed standardized definitions of the side effects of cancer immunotherapy to assist clinicians in treating patients.

Immunotherapies have revolutionized the treatment of solid tumor cancers, improving outcomes for patients globally. However, the antitumor mechanisms of these therapies are known to cause side effects called immune-related adverse events (irAEs).

The paper, published in the *Journal for Immunotherapy of Cancer* is the first set of consensus expert definitions relating to the diagnosis and management of side effects caused by immunotherapy, specifically immune checkpoint inhibitors. They provide a shared vocabulary for clinicians which will help standardize the application of clinical practice guidelines and support clinicians in offering the <u>best treatment</u> to patients.

Commenting on the publication, first author Professor Jarushka Naidoo, Academic Professor of Medical Oncology in the RCSI Department of Medicine, said, "This set of guidelines will prove an important resource in cancer immunotherapy <u>clinical trials</u> as well as enabling more research into the biomarkers that help us predict adverse effects in patients."

Professor Naidoo and co-author Dr. Catherine Murphy, Oncology Specialist Registrar, Beaumont RCSI Cancer Centre assembled an <u>expert panel</u> with the Society for Immunotherapy of Cancer (SITC) to develop the definitions, addressing the unmet need for uniform terminology for different types of immune-related adverse events.

These had previously been inconsistently documented in literature and vary widely from short term inflammation to damage to organs. Over twenty oncology and immunotherapy specialists from academic



medicine, industry, patient advocacy and <u>regulatory agencies</u> were involved.

Immunotherapy helps the body to find and destroy <u>cancer cells</u>. It can treat many different types of cancer and can be used alone or in parallel with other cancer treatments such as chemotherapy.

**More information:** Jarushka Naidoo et al, Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology, *Journal for ImmunoTherapy of Cancer* (2023). DOI: 10.1136/jitc-2022-006398

# Provided by RCSI

Citation: International panel classifies immunotherapy side effects for the first time (2023, April 4) retrieved 28 April 2024 from <a href="https://medicalxpress.com/news/2023-04-international-panel-immunotherapy-side-effects.html">https://medicalxpress.com/news/2023-04-international-panel-immunotherapy-side-effects.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.